Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticCarcinoma, Squamous CellCombined Modality TherapyDose Fractionation, RadiationFollow-Up StudiesHead and Neck NeoplasmsHumansMitomycinPorfiromycinSurvival RateTime FactorsConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial